's () Neil Crabb caught up with Proactive London's Andrew Scott to update on recent developments with its portfolio companies.
Among a number of highlights they've increased its stake in artificial intelligence (AI) firm Celerum Limited to 33.8% from 10% as well as Exscientia, which has begun phase 1 clinical trials of DSP-1181, the world’s first drug created by artificial intelligence (AI).
''The industrial traction is really important to us - it's not primarily about investment, it's about showing industry engagement and that's an underlying theme of a lot of the activity and our ability to add value within that''.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE